Optimization of Ritonavir Preformulation: Techniques and Approaches for Enhancing Drug Formulation

ABSTRACT: Background: Excipients are essential for creating a stable, safe, and effective dosage form. A natural polymer called Lapidium Sativum lyophilized powder was used to create a co-processed excipient. Drug excipient compatibility was examined using a range of approaches, including DSC, infrared (FT-IR) Fourier transform spectroscopy, particle X-ray diffraction, after first drug identification and preformulation process development. Aim: The preformulation research aims to provide an elegant, simple, and cost-effective approach for determining Ritonavir in bulk dosage forms, as well as an in-vitro study. Methods: Ritonavir absorbs at 290 nm. Curves for calibration are displayed across specified wavelengths, and they were determined to be straight between 5 and 30 mcg/ml. The recovery experiments demonstrated the suggested methods accuracy, and the findings were validated in accordance with ICH recommendations. Precision and accuracy investigations were conducted, and good findings were obtained. Result: The validity of Ritonavir was confirmed by DSC and FITR spectra. Ritonavir concentrations in bulk and blood plasma were determined using a UV spectrophotometric technique. Research were conducted into the level of saturation solubility, micromeritical characteristics, temperature of melting, pH, the humidity, and equilibrium profile. The UV method was continuous from 5 to 50 µg/mL. The small % CV values for intra-day and inter-day variations indicated the proposed technique's resilience. A very high regression coefficient value of 0.999 indicated the robustness of the approach. The physicochemical evaluation of the medication indicated RIT's appropriateness for the oral route. Conclusion: In brief, pharmaceutical preformulation investigations were conducted to ensure the successful creation of coprocessed excipients for safe and effective formulation development.